Maky Zanganeh (#3343)
- $ 1 B
- Biotech
- United States
- F
- 55 Years
Mira Murati’s deposition pulled back the curtain on Sam Altman’s ouster
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
Mulvihill Enhanced Split Preferred Share ETF Declares Monthly Distribution
TOUCHMARK BANCSHARES, INC. REPORTS FIRST QUARTER RESULTS
Kevin Hassett Says It’s Good Sign Americans Using Credit Cards More As Iran War Blows Up Their Budgets
Iran war threatens jet fuel shortage that could disrupt summer travel in Asia and Europe
'This Is Yours!': Whoopi Goldberg Turns Marco Rubio's Words For Iran Against Him
Catalyst Professorship fosters collaboration with the private sector
Anthropic CEO Predicts SaaS Pivot as AI Coding Surges
PRISM MarketView Launches Emerging Semiconductors Index
About Me
Maky Zanganeh is co-CEO of Summit Therapeutics, a biotech firm with a promising drug candidate to treat lung cancer. She owns just under 5% of the company's stock. Zanganeh, an immigrant from Iran, previously served as chief operating officer of drug firm Pharmacyclics, which was acquired by AbbVie for $21 million in 2015. Zanganeh first came to the U.S. to work for robotic surgery firm Computer Motion in 2002 after running the company's European operations. Zanganeh runs Summit Therapeutics as co-CEO with Robert (Bob) Duggan, who became a billionaire after investing in and running Pharmacyclics. She and Duggan married in 2024. She trained as a dentist at university in Strasbourg, France and then obtained an MBA while first working at Computer Motion.
Achievements
Career Highlights
A snapshot of the defining milestones, leadership decisions, and breakthroughs that shaped Maky Zanganeh’s rise and global influence.
Wealth Growth
Net Worth Growth Over Time
Tracking Maky Zanganeh’s net worth journey over the years, highlighting key growth phases and financial milestones.
© Iconic Billionaires